Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Maze Therapeutics Inc (MAZE)

165 + Investors. Track Smart Money conviction in MAZE. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +22
Streak
5Q ▲
Buyers last Q
63%

Smart Money Signals — MAZE

Based on 166 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 5 quarters in a row

last 6Q
For 5 consecutive quarters, more hedge funds added MAZE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
166 hedge funds hold MAZE right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +148% more funds vs a year ago

fund count last 6Q
+99 new funds entered over the past year (+148% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 63% buying

107 buying64 selling
Last quarter: 107 funds were net buyers (49 opened a brand new position + 58 added to an existing one). Only 64 were sellers (37 trimmed + 27 sold completely). A clear majority buying is a strong confirmation signal.
⚠️

Fewer new buyers each quarter (-10 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 13 → 23 → 59 → 49. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔄

Mostly new holders — 58% entered in last year

■ 2% conviction (2yr+) ■ 39% medium ■ 58% new
Only 4 funds (2%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💎

Buying through price weakness — shares +8%, value -23%

Value
-23%
Shares
+7%
Last quarter: funds added +8% more shares while total portfolio value only changed -23%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
🚀

Acceleration phase — new buyers rushing in

67 → 13 → 23 → 59 → 49 new funds/Q
New funds entering each quarter: 13 → 23 → 59 → 49. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🌱

Early stage — 95% of holders entered in last year

■ 5% veterans ■ 0% 1-2yr ■ 95% new
Of 174 current holders: 165 (95%) entered in the past year, only 9 (5%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
📋

Smaller funds dominant — 15% AUM from top-100

15% from top-100 AUM funds
39 of 166 holders rank in the top 100 by AUM, but together hold only 15% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
6.5
out of 10
Moderate Exit Risk
Exit risk score 6.5/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — MAZE

In 2026 Q1, 107 hedge funds were net buyers of MAZE (49 opened a new position, 58 added to an existing one), while 64 reduced or exited (37 trimmed, 27 sold completely) — a 63% buyer ratio, indicating clear institutional accumulation. This marks 5 consecutive quarters of net institutional buying — a persistent conviction signal. Net fund flow last quarter: +22 funds (more new holders than closures). Total institutional holders: 166.

Hedge Fund Ownership: MAZE

How many hedge funds hold MAZE — quarterly history vs. share price
Quarterly hedge fund ownership of MAZE vs. share price

Market Analysis: MAZE

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: MAZE

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Maze Therapeutics Inc (MAZE) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much MAZE has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 79d ago
MAZE
-16.8%
XLV
+2.8%

MAZE outperformed XLV by -19.6% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 34d ago
MAZE
-2.8%
XLV
+3.9%

Since the filing became public, MAZE outperformed XLV by -6.7% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

20 top-rated funds 11 high-conviction
Consensus
5.7
/ 10
breadth
×
Elite
4.9
/ 10
conviction
Hedge Fund Positioning: MAZE
165 + Investors

Track Smart Money conviction in MAZE. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 165 144 14.58%
13F Shares 52M 48M 7.6%
Total Value $1.54B $2.00B -23.14%
New Positions 48 59 -11
Increased Positions 58 46 +12
Closed Positions 27 7 +20
Reduced Positions 36 20 +16
Total Calls 7 2 250.0%
Total Puts 5 0 100%
PUT/CALL Ratio 0.71 0.0 Neutral

Statistics: MAZE

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

165 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in MAZE. Verified SEC 13F-HR filings.

QUARTER:
Top 25 MAZE holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Trv GP IV, LLC 50.04% 4,473,958 $133.5M
2 ARCH Venture Management, LLC 18.16% 4,120,053 $123.0M
3 General Catalyst Group Management, LLC 16.85% 1,035,910 $30.9M
4 Trv GP V, LLC 7.08% 950,800 $28.4M
5 Washington University 5.23% 280,802 $8.4M
6 a16z Capital Management, L.L.C. 3.94% 1,702,225 $50.8M
7 Frazier Life Sciences Management, L.P. 3.51% 4,567,274 $136.3M
8 Squadron Capital Management LLC 2.82% 257,500 $7.7M
9 Ally Bridge Group (NY) LLC 2.41% 100,000 $3.0M
10 Foresite Capital Management IV, LLC 1.98% 156,901 $4.7M
11 Logos Global Management LP 1.84% 1,235,000 $36.9M
12 Venrock Adviser, LLC 1.78% 1,602,034 $47.8M
13 Casdin Capital, LLC 1.72% 758,857 $22.7M
14 Deep Track Capital, LP 1.70% 3,477,562 $103.8M
15 Paradigm Biocapital Advisors LP 1.67% 2,744,399 $81.9M
16 Mass General Brigham, Inc 1.53% 239,994 $7.2M
17 Spruce Street Capital LP 1.44% 200,000 $6.0M
18 Exome Asset Management LLC 1.37% 88,510 $2.6M
19 Caligan Partners LP 1.22% 614,962 $18.4M
20 Cormorant Asset Management, LP 1.12% 750,000 $22.4M
21 Sphera Funds Management LTD. 1.08% 227,343 $6.8M
22 Alphabet Inc. 1.03% 1,388,583 $41.4M
23 Ikarian Capital, LLC 0.92% 378,999 $11.3M
24 Propel Bio Management, LLC 0.82% 43,798 $1.3M
25 HighVista Strategies LLC 0.82% 99,850 $3.0M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Maze Therapeutics Inc (MAZE)

What does the Smart Money Trend signal show for MAZE?

Buying streak — 5 quarters in a row: For 5 consecutive quarters, more hedge funds added MAZE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for MAZE?

More buyers than sellers — 63% buying: Last quarter: 107 funds were net buyers (49 opened a brand new position + 58 added to an existing one). Only 64 were sellers (37 trimmed + 27 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for MAZE holders?

Smaller funds dominant — 15% AUM from top-100: 39 of 166 holders rank in the top 100 by AUM, but together hold only 15% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held MAZE?

Mostly new holders — 58% entered in last year: Only 4 funds (2%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Maze Therapeutics Inc (MAZE) following the 2026 Q1 hedge fund 13F filings?

As of today, MAZE has moved -2.8% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of -6.7%. Since the quarter end (March 31, 2026), MAZE has gained -16.8% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →